Aim To investigate CD133 expression and its relationship to clinicopathological profile in colorectal cancer (CRC) patients. Methods This cross-sectional study was performed at the Internal Medicine Department, School of Medicine, Adam Malik General Hospital. The colorectal cancer tissue was taken from surgical resection and colonoscopy biopsy from CRC patients. Clinical profile was obtained by a questionnaire. Histopathology examination was done using hematoxylin and eosin staining. Immunohistochemistry (distribution score and intensity score) combined with ROC analysis were conducted to determine CD133 expression. An association between CD133 expression and clinicopathological profile was then analyzed. Results Out of 118 patients, 690 (58.5%) were male. The high and low level of CD133 expression were found in 44 (37.3%) and 74 (62.7%) patients, respectively. No difference between gender, age, body mass index, hemoglobin, leucocytes, platelets, and histopathology with CD133 expression was found. There was a significant difference between CD133 and different CRC locations (p=0.002). CD133 expression was higher in the proximal colon than the rectum (p=0.002), and it was higher in the distal colon than the rectum (p=0.008), especially in terms of percentages of stained cancer cells (distribution score). Conclusion CD133 expression was associated with the tumour location, but not with other clinicopathological factors.
Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. CA Cancer J Clin. 2012;87–108.
2.
Effendi R, Efendi D, Dairy L, Sembiring J, Sihombing M, Marpaung B, et al. Profile of colorectal cancer patients in Endoscopic Unit at Dr. Pirngadi Hospital-Medan. Indones J Gastroenterol Hepatol Dig Endosc. 2008;78–81.
3.
Rey I, Effendi R, Zain L. Comparison of CEA level among tumor location and histopathological findings in colorectal cancer. J Gastroen Hepatol. 2016;200.
4.
Kobayashi H, Mochizuki H, Sugihara K, Morita T, Kotake K, Teramoto T, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery. 2007;67–75.
5.
Reya T, Morrison S, Clarke M, Weissman I. Stem cells, cancer, and cancer stem cells. Nature. 2001;105–11.
6.
Visvader J, Lindeman G. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;755–68.
7.
Song L, Li Y, He B, Gong Y. Development of small molecules targeting the Wnt signaling pathway in cancer stem cells for the treatment of colorectal cancer. Clin Colorectal Canc. 2015;133–45.
8.
Zhou Y, Xia L, Wang H, Oyang L, Su M, Liu Q, et al. Cancer stem cells in progression of colorectal cancer. Oncotarget. 2018;33403–15.
9.
Munro M, Wickremesekera S, Peng L, Tan S, Itinteang T. Cancer stem cells in colorectal cancer: a review. J of Clin Pathol. 2018;110–6.
10.
Corbeil D, Röper K, Hellwig A, Tavian M, Miraglia S, Watt S, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 2000;5512–20.
11.
Ong C, Kim L, Kong H, Low L, Iacopetta B, Soong R, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Modern Pathol. 2010;4507.
12.
Fleming M, Ravula S, Tatishchev S, Wang H. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol. 2012;153–73.
13.
Kato Y, Nishihara H, Mohri H, Kanno H, Kobayashi H, Kimura T, et al. Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma. Brain Tumor Pathol. 2014;23–30.
14.
Horst D, Kriegl L, Engel J, Kirchner T, Jung. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 2009;844–50.
15.
Hong I, Hong S, Chang Y, Lee W, Lee B, Kang Y, et al. Expression of the cancer stem cell markers CD44 and CD133 in colorectal cancer: an immunohistochemical staining analysis. Ann Coloproctol. 2015;84–91.
16.
Nosrati A, Naghshvar F, Maleki I, Salehi F. Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran. Gastroenterol Hepatol Bed Bench. 2016;132–9.
17.
Cook M, Dawsey S, Freedman N, Inskip P, Wichner S, Quraishi S, et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev. 2009;1174–82.
18.
Gabory A, Attig L, Junien C. Sexual dimorphism in environmental epigenetic programming. Mol Cell Endocrinol. 2009;8–18.
19.
Brait M, Ford J, Papaiahgari S, Garza M, Lee J, Loyo M, et al. Association between lifestyle factors and CpG island methylation in a cancer-free population. Cancer Epidemiol Biomarkers Prev. 2009;2984–91.
20.
Bollati V, Baccarelli A. Environmental epigenetics. Heredity. 2010;105–12.
21.
Hongo K, Kazama S, Sunami E, Tsuno N, Takahashi K, Nagawa H, et al. Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer. Med Oncol. 2012;2849–57.
22.
Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol. 2010;707–18.
23.
Huang R, Mo D, Wu J, Ai H, Lu Y. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies. Medicine. 2018;e10446.
24.
Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci. 2008;1578–83.
25.
Chew M, Teoh K, Cheah P. CD133 marks for colorectal adenocarcinoma. Malay J Pathol. 2012;25–8.
26.
Aoyama T, Kashiwabara K, Oba K, Honda M, Sadahiro S, Hamada C, et al. Clinical impact of tumor location on the colon cancer survival and recurrence: analyses of pooled data from three large phase III randomized clinical trials. Cancer Med. 2017;2523–30.
27.
Jafarabadi M, Mohammadi S, Hajizadeh E, Kazemnejad A, Fatemi S. Does the prognosis of colorectal cancer vary with tumor site? Gastroenterol Hepatol Bed Bench. 2011;199–199.
28.
Chen S, Song X, Chen Z, Li X, Li M, Liu H, et al. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis. PloS One. 2013;5638.
29.
Tampellini M, Saini A, Alabiso I, Bitossi R, Brizzi M, Sculli C, et al. The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. Brit J Cancer. 2006;13–20.
30.
Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, Mckay R, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α. Oncogene. 2009;3949–59.
31.
Seidel S, Garvalov B, Wirta V, Stechow V, Schänzer L, Meletis A, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2α. Brain. 2010;983–95.
32.
Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, et al. mTOR signal and hypoxia-inducible factor-1α regulate CD133 expression in cancer cells. Cancer Res. 2009;7160–4.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
